The paraventricular nucleus of the thalamus (PVT) appears to participate in drug addiction. Recent evidence in rats shows that ethanol drinking is increased by orexin/hypocretin (OX) afferents from the hypothalamus, acting specifically in the anterior (aPVT) rather than posterior (pPVT) PVT subregion. The present study sought to identify neuropeptides transcribed within the PVT, which themselves might contribute to ethanol drinking and possibly mediate the actions of OX. We discovered that substance P (SP) in the aPVT can stimulate intermittent-access ethanol drinking, similar to OX, and that SP receptor [neurokinin 1 receptor/tachykinin receptor 1 (NK1R)] antagonists in this subregion reduce ethanol drinking. As with OX, this effect is site specific, with SP in the pPVT or dorsal third ventricle having no effect on ethanol drinking, and it is behaviorally specific, with SP in the aPVT reducing the drinking of sucrose and stimulating it in the pPVT. A close relationship between SP and OX was demonstrated by a stimulatory effect of local OX injection on SP mRNA and peptide levels, specifically in the aPVT but not pPVT, and a stimulatory effect of OX on SP expression in isolated thalamic neurons, reflecting postsynaptic actions. A functional relationship between OX and SP in the aPVT is suggested by our additional finding that ethanol drinking induced by OX is blocked by a local NK1R antagonist administered at a sub-threshold dose. These results, suggesting that SP in the aPVT mediates the stimulatory effect of OX on ethanol drinking, identify a new role for SP in the control of this behavior.
INTRODUCTION
The paraventricular nucleus of the thalamus (PVT) has been suggested to participate in the neurocircuitry of addiction (Matzeu, Zamora-Martinez & Martin-Fardon 2014) . This nucleus, the only area of the thalamus that projects to limbic regions involved in drug seeking (Vertes & Hoover 2008) , affects functions related to addiction, including arousal, nociception, stress, and homeostasis (Kolaj et al. 2014) . The PVT appears to have a particular relationship with ethanol drinking, with its neurons activated under conditions of both ethanol seeking (Dayas et al. 2008; Hamlin et al. 2009 ) and intake (Ryabinin et al. 1997; Barson, Ho & Leibowitz 2015) , and with lesions of the PVT preventing the reinstatement of beer seeking (Hamlin et al. 2009 ).
The anterior (aPVT) and posterior (pPVT) subregions of the PVT may differ in their role in addiction (Flagel et al. 2011; Barson et al. 2015) , possibly because of their connectivity to other brain regions (Vertes & Hoover 2008) . While the aPVT sends stronger projections than the pPVT to certain brain areas implicated in drug seeking, such as the nucleus accumbens core, medial prefrontal cortex, and ventral subiculum, the pPVT has a larger projection to areas implicated in anxiety, including the central nucleus of the amygdala (Li & Kirouac 2008; Vertes & Hoover 2008) . Support for this differential role of the PVT subregions in addiction comes from evidence obtained with orexin/hypocretin (OX), an orexigenic neuropeptide transcribed almost exclusively within neurons of the hypothalamus, with a few additional cells at the junction of the hypothalamus and thalamus (Peyron et al. 1998; Sakurai et al. 1998) . This neuropeptide sends one of its densest projections to the PVT subregions (Peyron et al. 1998; Kirouac, Parsons & Li 2005) where both of its receptors, OX1R and OX2R, are expressed (Marcus et al. 2001) . With OX2R targeted by both OX isoforms, OX-A and OX-B, while OX1R is primarily targeted by OX-A (Sakurai et al. 1998) , our findings in the aPVT that both OX-A and OX-B promote ethanol drinking and that an OX2R but not OX1R antagonist suppresses it (Barson et al. 2015) support the specific involvement of OX2R in the aPVT in stimulating ethanol drinking. This is in contrast to the pPVT, where OX does not affect ethanol drinking but instead promotes palatable food intake (Choi et al. 2012; Barson et al. 2015) . This evidence, supporting a role for hypothalamic OX projections in promoting ethanol drinking through their actions at OX2R in the aPVT, has led us to investigate neuropeptides transcribed within the PVT itself that may also be involved in this behavior and possibly in mediating the actions of OX.
Based on limited published evidence, we focused on the neuropeptide, substance P (SP), as a possible candidate involved in the PVT promotion of ethanol drinking. Studies have shown that systemic injection of antagonists of the SP receptor, neurokinin 1 receptor/tachykinin receptor 1 (NK1R), can reduce ethanol intake and seeking as well as the motivation to obtain ethanol (Steensland et al. 2010; Schank et al. 2011; Schank et al. 2013) and that mice that are genetically deficient in NK1R drink less ethanol at high concentrations than do wild-type controls (George et al. 2008) . Also, in alcohol-preferring P rats, whereas SP injection at moderate-to-high levels in the amygdala reduces the self-administration of ethanol (Yang et al. 2009) , the finding that an NK1R antagonist injected into this nucleus leads to the same suppression of ethanol self-administration (Schank et al. 2013) supports the idea that endogenous SP functions normally in the amygdala to stimulate ethanol intake. This neuropeptide may have similar actions in the PVT, where it has been detected in perikarya and fibers (McLean, Skirboll & Pert 1985; Battaglia, Spreafico & Rustioni 1992) and NK1R has also been described (Mantyh, Hunt & Maggio 1984) . The idea that SP in the PVT may function in close relation to OX is suggested by the finding that expression of tachykinin precursor 1, which encodes SP, is enhanced in the amygdala of dogs with a mutation of OX2R (Lindberg et al. 2007) and that OX1R in rats is expressed on SP-containing dorsal root ganglion neurons (Colas et al. 2014) . These studies hint at the possibility that SP may function in close relation to OX, acting in the PVT to stimulate ethanol drinking.
To investigate the role of SP in the PVT, we first examined the impact of this neuropeptide in the PVT subregions on a preclinical model of alcohol abuse (Carnicella, Ron & Barak 2014) , intermittent-access ethanol drinking, using microinjections of SP and NK1R antagonists. Then, with OX afferents also found to alter ethanol intake, we explored the relationship between OX and SP in the PVT through measurements of gene and protein expression as well as ethanol drinking. Together, these experiments tested the hypothesis that SP transcribed within the PVT influences high ethanol intake and that this occurs specifically in the aPVT in response to stimulation by OX.
MATERIALS AND METHODS
See Supporting Information for further details.
Subjects
Adult, male Long-Evans rats (N = 178; 250-275 g, Charles River Laboratories International, Inc., Kingston, NY, USA) and timed-pregnant female Long-Evans rats (embryonic day 9, N = 10; Charles River Laboratories International) were individually housed in an AAALACaccredited facility, on a 12-hour reversed light/dark cycle (lights off at 0900 hours for male rats; lights off at 1200 hours for female rats). All rats were given at least 1 week after arrival to acclimate to the facility prior to testing. They received ad libitum chow (PicoLab Rodent Diet 20 5053, Lab Diet, St. Louis, MO, USA) and filtered water unless otherwise specified. Male rats received water via two plastic 8-oz bottles (PETCO Animal Supplies, Inc, San Diego, CA, USA). Experiments were approved by the Institutional Animal Care and Use Committee of The Rockefeller University and followed the NIH Guide for the Care and Use of Laboratory Animals.
Experimental protocol
Seven experiments were performed to investigate the role of SP in the PVT ( Figure S1 ). Experiments 1 and 2 examined the impact of SP in the PVT on intermittent-access 20 percent ethanol drinking. Experiments 3-5 determined if SP gene expression and peptide levels in the PVT are affected by OX. Experiment 6 directly compared the effects of the OX isoforms in the PVT on ethanol drinking. Lastly, Experiment 7 tested if the integrity of the SP system is necessary for OX to exert this effect on ethanol drinking.
Experiment 1
To examine the impact of SP in the PVT on ethanol drinking, rats (N = 30) were trained to drink 20 percent ethanol over 2 weeks and then cannulated in the aPVT or pPVT or in the adjacent dorsal third ventricle (d3v), which served as an anatomical control against leakage into the ventricle (n = 10/area). After anesthesia with 75 mg/kg ketamine and 10 mg/kg xylazine (intraperitoneal), 10-mm guide shafts (21-gage stainless steel) were implanted perpendicularly, aimed at the aPVT (posterior (P) À1.7 mm, lateral (L) ±0.2 mm, ventral (V) À4.6 mm), pPVT (P À3.4 mm, L ±0.2 mm, V À4.6 mm), or d3v (P À2.5 mm, L ±0.2 mm, V À3.9 mm), relative to bregma (P), the midsaggital sinus (L), and level skull surface (V) (Paxinos & Watson 2005) . Prior to lowering the guide shaft into place, the midsaggital sinus was gently moved to the side. Injectors protruded 1 mm beyond the guide shafts, and to prevent occlusion, stainless steel stylets were left in the guide shafts between injections. Rats were given at least 1 week of recovery after surgery before receiving their first set of injections (described below) and then at least 1 additional week of recovery before SP injections. For these tests, they were injected with SP (0.075, 0.750, and 7.500 nmol; American Peptide, Sunnyvale, CA, USA), counterbalanced against saline vehicle (0.3 μl; Hospira Inc., Lake Forest, IL, USA), in a within-subject Latin square design across 4 ethanol-access days. These doses of SP were chosen based on prior studies showing the middle and high doses to reduce ethanol drinking after injection in the amygdala but not caudate putamen (Yang et al. 2009 ). To determine if the effects of SP were specific to ethanol intake, a different set of rats (N = 20) was trained over 2 weeks to drink 2 percent sucrose, which is consumed at comparable levels to 20 percent ethanol when measured in g/kg/24 hours (Li et al. 2011; Barson et al. 2015) . They were then cannulated in the aPVT or pPVT (n = 10/area) and injected with the middle dose of SP (0.750 nmol; American Peptide) counterbalanced against saline vehicle (0.3 μl; Hospira Inc.) in a within-subject Latin square design across 2 sucrose days. Following injections, intake of ethanol or sucrose as well as simultaneously available food and water was measured at 0.5, 1, 2, and 4 hours. (See Supporting Information for details of ethanol and sucrose drinking and microinjections.)
Experiment 2
To determine if the effects of SP injection on ethanol drinking reflect endogenous SP activity, the ethanoldrinking rats from Experiment 1, which had cannulas in the aPVT or pPVT (n = 10/area), were tested 1 week after surgery by being injected with the NK1R antagonist, L-733,060 hydrochloride (0.5, 5.0 nmol; Tocris Bioscience, Minneapolis, MN, USA), counterbalanced against saline vehicle (0.3 μl; Hospira Inc.) in a within-subject Latin square design across 3 ethanol days. These antagonist doses were selected based on prior studies showing their central injection to antagonize the effects of SP and to alter pain processing (Hamity et al. 2010; Chai et al. 2012) . Then, 2 weeks after recovery from SP injections (Experiment 1), they were injected with the specific NK1R antagonist RP 67580 (0.5, 5.0 nmol; Tocris) counterbalanced against dimethyl sulfoxide vehicle (0.3 μl; Sigma-Aldrich, St. Louis, MO, USA) in a withinsubject Latin square design across 3 ethanol days. Following injections, intake of ethanol, food, and water was measured at 0.5, 1, 2, and 4 hours.
Experiment 3
To determine if SP is affected by OX, which in the PVT alters ingestive behavior, a new set of ethanol-naïve rats (N = 48) was cannulated in the aPVT or pPVT (n = 24/ area) and given 1 week of recovery before testing. They were then injected with OX-A (1.0 nmol; American Peptide), OX-B (1.0 nmol; American Peptide), or saline vehicle (0.3 μl; Hospira Inc.), in a between-subject design (n = 8/treatment/area). These OX doses are high enough to effectively promote ethanol drinking (Barson et al. 2015) and are the same or lower than those used to induce feeding (Sweet et al. 1999 ) and emotional behaviors (Li et al. 2009; Li et al. 2010) . Following microinjection, food was removed, and rats were sacrificed 60 minutes later via rapid decapitation. The area injected was then dissected out and stored at À40°C in RNAlater (SigmaAldrich) until mRNA extraction and analysis with quantitative real-time polymerase chain reaction (qRT-PCR). (See Supporting Information for details of brain dissections and qRT-PCR.)
Experiment 4
To determine if SP peptide levels in the PVT are also affected by OX, an additional set of ethanol-naïve rats (N = 30) was cannulated in the aPVT or pPVT (n = 15/ area) and injected as in Experiment 3 (n = 5/treatment/ area). Following injection, food was removed, and rats were sacrificed 90 minutes later via rapid decapitation. The area injected was then dissected out, flash-frozen in cold isopentane (À25°C), and stored at À80°C until analysis of SP peptide levels with enzyme-linked immunosorbent assay (ELISA). (See Supporting Information for details of ELISA.)
Experiment 5
To determine if the effect of OX is postsynaptic and involves neurons expressing SP, primary thalamic neurons were isolated from embryonic day 19 embryos of pregnant dams (N = 10) and were treated with OX-A (50 and 100 nM; American Peptide), OX-B (50 and 100 nM; American Peptide), or untreated (control group) in a within-subject design, with three to four wells of neurons from a dam used per treatment sample. These doses of OX are close to the half-maximal concentration and double the half-maximal concentration required for increasing cytoplasmic Ca 2+ levels by both OX-A and OX-B acting at the OX2R and by OX-A acting at the OX1R (Sakurai et al. 1998 
Experiment 6
To directly compare the effects of the OX isoforms in the PVT on ethanol drinking and ensure that the effects are not due to leakage into the adjacent ventricle, rats (N = 20) were trained to drink 20 percent ethanol over 2 weeks and then cannulated in the aPVT or pPVT (n = 10/area). After recovery from surgery, the rats were injected with OX-A (1.0 nmol; American Peptide) counterbalanced against OX-B (1.0 nmol; American Peptide) and saline vehicle (0.3 μl; Hospira Inc.) in a within-subject Latin square design across 3 ethanolaccess days. Rats with cannulas in the d3v, described in Experiment 1, were tested after 1 week of recovery from surgery (n = 10). Following injections, intake of ethanol, food, and water was measured at 0.5, 1, 2, and 4 hours.
Experiment 7
To determine if the integrity of the SP system is necessary for OX to affect ethanol drinking, rats were trained to drink 20 percent ethanol and then cannulated in the aPVT or pPVT (N = 20). After recovery, they were injected with: (1) the NK1R antagonist L-733,060 hydrochloride (0.5 nmol; Tocris) followed 15 minutes later by OX-B (1 nmol; American Peptide); (2) saline (0.3 μl; Hospira Inc.) followed by OX-B (1 nmol); or (3) saline followed by saline, in a within-subject Latin square design across 3 ethanol days. Following injections, intake of ethanol, food, and water was measured at 0.5, 1, 2, and 4 hours.
RESULTS

Histology, ethanol drinking, and blood ethanol concentration
Histological examination showed that aPVT injections were made between bregma À1.44 and À1.92 mm, pPVT injections were between À3.00 and À3.48 mm, and d3v injections were between À2.16 and À2.64 mm ( Figure S2 ). Analysis of the diffusion of 0.3-μl methylene blue dye after injection in the aPVT showed that it never reached the pPVT, and vice versa, and that it had a radial spread of approximately 0.5 mm. Under the 20 percent ethanol intermittent-access, two-bottle-choice paradigm, the rats (N = 67) drank an average of 4.0 ± 0.4 g/kg of ethanol in 24 hours and 0.7 ± 0.1 g/kg of ethanol in the first 30 minutes of daily access. When measured after 30 minutes of access, their blood ethanol concentrations averaged 53.4 ± 4.5 mg/dl and went as high as 121.2 mg/dl. These concentrations were predicted significantly by the 30-minute intake prior to blood collection (R 2 = +0.89, P < 0.0001) ( Figure S3 ). Under the 2 percent sucrose intermittentaccess paradigm, the rats (N = 20) drank an average of 3.6 ± 0.3 g/kg of sucrose in 24 hours and 0.6 ± 0.1 g/kg of sucrose in the first 30 minutes of daily access.
Experiment 1: substance P specifically in the anterior PVT selectively stimulates ethanol drinking
In rats trained to drink ethanol, results with injection of SP into the aPVT revealed a significant main effect of drug on ethanol intake [F(3,27) = 3.87, P < 0.05] and a significant interaction effect between drug and time [F(6,54) = 7.33, P < 0.001] (Fig. 1a) . Pairwise comparisons demonstrated that both the low (0.075 nmol) and middle (0.750 nmol) doses of SP in the aPVT compared with vehicle significantly increased ethanol drinking (P < 0.05), while the highest dose (7.500 nmol) had no effect, and tests of the simple effects showed that the low dose stimulated intake at 30 minutes and 1 hour post-injection (P < 0.01 and P < 0.05, respectively) and the middle dose stimulated intake at 1 and 2 hours post-injection (P < 0.05 and P < 0.01, respectively). Analysis of the intake of simultaneously available water and food showed this SP effect to be specific to ethanol, with no main effects observed on the intake of either water [F(3,27 (Table S2 ). These results confirm that the increase in ethanol intake induced by injection in the aPVT reflects a local response, one that is not due to the spread of SP to nearby brain regions.
To determine if effects were specific to ethanol, analysis of SP in the aPVT of rats trained to drink sucrose demonstrated that this injection significantly reduced the drinking of sucrose, leading to a significant main effect on sucrose intake [F(1,9) = 5.61, P < 0.05], with no significant interaction effect between drug and time [F(2,18) = 1.78, NS] (Fig. 1b) . This is in contrast to the pPVT, where results demonstrated that SP enhanced sucrose drinking, leading to a significant main effect on sucrose intake [F(1,9) = 4.78, P < 0.05], with no significant interaction effect between drug and time [F(2,18) = 1.34, NS] (Fig. 1b) . In these sucrose-drinking rats, there were no significant main effects of SP injection in the aPVT on intake of water [F(1,9) = 0.74, NS] or food [F(1,9) = 0.08, NS] or in the pPVT on intake of water [F(1,9) = 0.27, NS] or food [F(1,9) = 0.46, NS] (data not shown). These results reveal a double dissociation in the subregion-specific effects of SP on consummatory behavior, with SP in the aPVT selectively stimulating intake of the drug ethanol and SP in the pPVT selectively stimulating intake of the palatable food, sucrose.
Experiment 2: substance P receptor antagonists in the anterior PVT reduce ethanol drinking
To determine if the effects of SP on ethanol drinking reflect endogenous SP activity, rats trained to drink ethanol were injected with NK1R antagonists. The results showed that L-733,060 in the aPVT led to a significant main effect on ethanol intake [F(2,18) = 5.67, P < 0.05], with no significant interaction effect between drug and time [F(4,36) = 0.41, NS] (Fig. 2a) . Pairwise comparisons revealed a significant decrease in ethanol drinking at the high dose of this NK1R antagonist (5.0 nmol) in the aPVT as compared with vehicle (P < 0.05), opposite to that induced by SP in Experiment 1, with no significant effect at the low dose (0.5 nmol) (NS). There were no main effects of this antagonist on the intake of water [F(2,18) = 1.57, NS] or food [F(2,18) = 3.17, NS] (data not shown). In contrast to the aPVT, results from injections of L-733,060 in the pPVT showed no significant main effects on the intake of ethanol [F(2,18) = 0.89, NS] (Fig. 2a) (Fig. 2b) . Pairwise comparisons revealed a significant decrease in ethanol drinking with RP 67580 in the aPVT at the high dose (5.0 nmol) compared with vehicle (P < 0.05). Again, in the pPVT, there were no significant main effects of this antagonist on ethanol intake [F(2,18) = 1.59, NS] (Fig. 2b) To determine if SP gene expression in the PVT is affected by OX, which has previously been found to affect ethanol drinking, analysis of the aPVT using qRT-PCR revealed a significant main effect of OX on local levels of SP mRNA [F(2,21) = 10.41, P < 0.001], with post hoc tests showing a significant increase in the gene expression of SP after injection of OX-B (+219 percent, P < 0.001) and a trend for an increase after injection of OX-A (+116 percent, P = 0.06) (Fig. 3) . In contrast, in the pPVT, the significant main effect of OX injection on SP mRNA [F(2,21) = 10.19, P < 0.01] reflected a significant decrease in mRNA levels in response to both OX-B (À54 percent, P < 0.01) and OX-A (À50 percent, P < 0.01) (Fig. 3) . Results also showed a main effect of OX on mRNA levels of the opioid enkephalin (ENK) in the aPVT [F(2,21) = 4.17, P < 0.05]; however, post hoc tests failed to reveal a significant change in ENK in response to either OX-A or OX-B (NS), and there were no significant main effects on ENK in the pPVT [F(2,21) = 0.49, NS] (Fig. 3) . Also, there was no significant main effect of OX on mRNA levels of the opioid dynorphin (DYN) in the aPVT [F(2,21) = 2.62, NS] or pPVT [F(2,21) = 2.30, NS] (data not shown), and ΔΔC T values for this neuropeptide were an order of magnitude lower than for SP and ENK, indicating that DYN was expressed only at low levels. These results demonstrate that local gene expression of SP, but not the opioids, is significantly affected by OX, with opposite effects in the aPVT and pPVT.
Experiment 4: substance P peptide levels in the anterior PVT are increased by orexin-B
Using ELISA to examine SP peptide levels affected by OX injection in the PVT subregions, analysis of the aPVT revealed that OX compared with vehicle produced significant changes [F(2,12) = 8.57, P < 0.01], with post hoc tests showing this to be due specifically to OX-B, which produced a small but significant increase in SP peptide levels (P < 0.01), while OX-A produced no significant Table 1 ). This effect in the aPVT contrasts with that in the pPVT, where no main effect of OX on SP levels was observed [F(2,12) = 0.65, NS] (Table 1 ). These results demonstrate that OX-B but not OX-A in the aPVT increases local SP peptide levels, with neither OX isoform having a significant effect in the pPVT.
Experiment 5: increase in substance P expression induced by orexin-B is postsynaptic
To ensure that the effects of OX on SP are direct postsynaptic neuronal effects, isolated primary thalamic neurons were treated with OX and examined for changes in mRNA using qRT-PCR. Analysis revealed a significant main effect of OX on levels of SP [F(4,12) = 14.51, P < 0.01]. Treatment with OX-B increased gene expression of SP to a greater extent than OX-A, as revealed by a significant linear trend from within-subject contrasts [F(1,3) = 41.10, P < 0.01] (Fig. 4) . Follow-up tests showed that the OX-B doses significantly stimulated SP mRNA [F(2,8) = 14.07, P < 0.01] and that this varied by dose [F(1,4) = 21.94, P < 0.01], with paired comparisons revealing a significant increase at the higher dose (+101 percent, P < 0.01) and a trend for an increase at the lower dose (+23 percent, P = 0.06). A similar but smaller effect was seen with the OX-A doses, which significantly stimulated SP [F(2,6) = 8.06, P < 0.05] according to dose [F(1,3) = 14.21, P < 0.05], with only the higher but not lower dose . While pairwise comparisons showed both OX-A and OX-B compared with vehicle in the aPVT to stimulate ethanol drinking (P = 0.05 and P < 0.01, respectively), the effect size from OX-B was greater than from OX-A (η 2 P = 0.55 versus η 2 P = 0.47), and within-subject contrasts revealed a significant linear trend [F(1,9) = 10.86, P < 0.01], demonstrating that drinking after OX-B was significantly greater than after OX-A (Fig. 5) . Measurements of the intake of water and food showed that there were no main effects of OX agonists on water [F(2,18) = 2.82, NS] or food intake [F(2,18) = 0.16, NS] (data not shown), confirming the substance specificity of this effect. These results contrast with those in the pPVT, where the OX agonists had no significant main effects on intake of ethanol [F(2,18) = 1.26, NS] (Fig. 5) (Table S2) , further confirm that the increase in ethanol intake after injection in the aPVT was not due to the spread of OX to nearby brain regions. Instead, injection in the d3v led to a significant main effect on food intake [F(2,16) = 5.98, P < 0.05], which reflected a decrease in feeding that was similarly induced by injection of both OX-A and OX-B (P < 0.01 and P < 0.05, respectively) (Table  S2 ). These findings show that OX increases ethanol drinking in a site-specific manner, with OX-B having stronger effects than OX-A, and that these effects are similar to those observed with SP.
Experiment 7: substance P receptor antagonist blocks the effects of orexin-B in the anterior PVT To determine if the integrity of the SP system is necessary for the changes in behavior produced by OX, ethanoldrinking rats were first injected in the aPVT or pPVT with the lower dose of the NK1R antagonist, L-733,060 (0.5 nmol), which in Experiment 2 did not affect ethanol intake, and were then injected with OX-B, which generally showed stronger effects than OX-A on both ethanol drinking and SP expression. With injection in the aPVT, results revealed a significant main effect of drug on ethanol intake [F(2,16) = 4.03, P < 0.05]. Pairwise comparisons showed that pre-treatment with the sub-threshold dose of the NK1R antagonist completely blocked the stimulatory effect of OX-B in the aPVT on ethanol drinking (P < 0.05), with intake after the combined injection of these two drugs showing no difference from intake after vehicle (NS) (Fig. 6) . Tests of the simple effects in the aPVT showed that the significant interaction effect between drug and time F(4,32) = 3.64, P < 0.05] was due to a significant stimulatory effect of OX-B on ethanol intake at 30 minutes and 2 hours post-injection (P < 0.05), with a trend for increased intake Figure 5 Injection of orexin into the anterior paraventricular thalamus (aPVT) significantly stimulates ethanol drinking, with orexin-B (OX-B) having larger effects than orexin-A (OX-A) (Experiment 6). Injection of OX-A (1 nmol in 0.3 μl) or OX-B (1 nmol in 0.3 μl) compared with saline vehicle significantly increases intermittent-access 20 percent ethanol drinking with injection into the aPVT (n = 10), but not the posterior paraventricular thalamus (pPVT, n = 10) or adjacent dorsal third ventricle (d3v, n = 9) Data are mean ± standard error of the difference; **p < 0.01, *p < 0.05 versus vehicle at 1 hour post-injection (P = 0.06). In contrast, drug injections in the pPVT of OX-B alone or in combination with L-733,060 produced no significant main effect on ethanol intake [F(2,16) = 0.61, NS] (Fig. 6) , consistent with the lack of effect in this subregion of OX-B or this antagonist on ethanol drinking. There were also no significant main effects of these drugs on water intake with any injections in the aPVT [F(2,16 
DISCUSSION
This study identifies a new function for SP in subregions of the PVT. The results demonstrate that this neuropeptide, similar to OX, endogenously promotes intermittentaccess ethanol drinking through actions specifically in the aPVT, whereas it promotes in the pPVT intake of the food sucrose rather than the drug ethanol. Moreover, they show that SP in the aPVT is stimulated by OX, particularly OX-B, likely projecting from the hypothalamus and that SP plays a role in mediating the effects of OX in this brain region (Fig. 7) . These results provide support for the new idea that SP in the PVT contributes to addictive behavior, much like OX, a well-established target for drug addiction treatment (Khoo & Brown 2014) .
Our finding that SP injection in the aPVT stimulates ethanol consumption is the first evidence that SP itself can enhance ingestive behavior. While earlier studies have reported that moderate-to-high doses of SP in other brain regions suppress ethanol drinking (Nikolaev et al. 2002; Yang et al. 2009 ), the present study reveals a stimulatory effect of SP at low-to-moderate doses in the aPVT. This increase in ethanol drinking is consistent with studies showing ethanol self-administration and consumption to be reduced by systemic NK1R antagonists in rats and NK1R knockout in mice (George et al. 2008; Steensland et al. 2010; Schank et al. 2013) . The distinct effects of different doses of SP, with low levels promoting and high levels inhibiting ethanol drinking, are similar to findings with other neuropeptides, such as corticotropinreleasing factor, and with stress that interacts with corticotropin-releasing factor (Le et al. 2002; Uhart & Wand 2009 ), and they may explain the present finding of later drinking onset after the moderate compared with low dose of SP. Our additional findings that two different NK1R antagonists in the aPVT suppress ethanol drinking provide strong support for the idea that endogenous SP is responsible for this behavior. These results were obtained with RP 67580, which has a high affinity for rodent NK1R (Seabrook et al. 1996) and shows a high selectivity for this receptor (Beaujouan et al. 1993) , and with L-33,060, Figure 7 Potential pathways, nuclei, and neuropeptide systems involved in intermittent-access 20 percent ethanol drinking. Ethanol drinking is hypothesized to be promoted by orexin/hypocretin (OX) from the hypothalamus acting at the orexin 2 receptor (OX2R) on substance P (SP)-containing neurons in the anterior paraventricular thalamus (aPVT). Ethanol drinking can also increase levels of OX to further excite this aPVT pathway. In contrast, SP in the posterior paraventricular thalamus (pPVT) promotes sucrose drinking which has a stronger affinity for human NK1R (Seabrook et al. 1996) . The additional finding here that SP in the pPVT stimulates sucrose drinking underscores the behavioral and anatomical specificity of this peptide's action, with SP in the aPVT stimulating ethanol intake and SP in the pPVT stimulating palatable food intake. This effect in the pPVT of SP on sucrose drinking is consistent with evidence that a systemic NK1 antagonist reduces this behavior (Steensland et al. 2010) , lending further support for the idea that central SP promotes ingestive behavior.
Our evidence showing SP in the PVT to have similar behavioral effects as OX is an important step toward establishing a link between these neuropeptides. Specifically, like OX (Barson et al. 2015) , we show that SP stimulates ethanol drinking when injected into the aPVT and sucrose drinking when injected into the pPVT. Our additional finding that SP and OX injected into the adjacent third ventricle similarly suppress food and water intake not only confirms that the effects of these neuropeptides in the PVT are not due to leakage into the ventricle but also demonstrates that these peptides can have similar effects in multiple brain regions. This idea is supported by other studies, showing both SP and OX to reduce food intake when injected into the ventricle (Dib 1999; Yamanaka et al. 1999) , produce anxiety in an elevated plus maze when injected into the amygdala (Avolio et al. 2011; Bassi, de Carvalho & Brandao 2014) , and induce antinociception when injected into the periaqueductal gray (Bassi et al. 2007 , Azhdari Zarmehri et al. 2011 .
The similar effects of SP and OX in the PVT subregions may reflect a physical interaction between these neuropeptides, at least in the aPVT. The finding that OX increases gene expression and peptide levels of SP in this subregion is the first direct evidence for a close relationship between these neuropeptides. This is consistent with indirect evidence, showing that a mutation of OX2R decreases gene expression of tachykinin precursor 1 (Lindberg et al. 2007 ) and that OX1R exists on SPcontaining dorsal root ganglion neurons (Colas et al. 2014) . The smaller increase in SP peptide relative to mRNA levels may reflect the difference in the timing of their measurement, with levels possibly higher shortly after OX injection. The additional result that OX stimulates SP expression in isolated thalamic neurons confirms that the increase of SP in the aPVT is due to postsynaptic actions of OX on local neurons. In addition to affecting SPcontaining neurons in the PVT, it is possible that OX affects the release into the PVT of SP peptide from afferents from other brain regions, such as the Edinger-Westphal nucleus, mesopontine tegmentum, or raphe nuclei (Otake 2005) . Although an OX2R antagonist is needed to show definitively that this OX-induced increase in SP is physiologically relevant, the OX dose used here was relatively low, and OX does not bind to NK1R (Gerashchenko et al. 2001; Hokfelt, Pernow & Wahren 2001) . In contrast to the aPVT, SP in the pPVT may not interact directly with OX. This is suggested by our evidence that SP peptide levels in this subregion were unaffected and mRNA levels were decreased by local OX. These effects in the pPVT may reflect actions of OX on presynaptic terminals (Kukkonen & Leonard 2014) or its interaction with other local neurochemicals such as glutamate (Huang, Ghosh & van den Pol 2006) . Together, this evidence focuses attention on SP in the aPVT as being directly and selectively stimulated by OX.
Our results indicate that the OX-induced release of SP into the aPVT has behavioral consequences. Specifically, the finding that OX-B-induced ethanol drinking is blocked by aPVT injection of an NK1R antagonist at a subthreshold dose suggests that the local release of SP is involved in mediating OX's ability in the aPVT to affect ingestive behavior. Levels of OX in the hypothalamus are elevated both during drug seeking (Harris, Wimmer & Aston-Jones 2005; Dayas et al. 2008) and after ethanol intake (Lawrence et al. 2006; Morganstern et al. 2010 , Barson et al. 2015 . Notably, antagonists of the OX and SP systems both reduce stress-induced ethanol seeking (Richards et al. 2008; Schank et al. 2014) . Because the aPVT is activated by an incentive stimulus (Flagel et al. 2011) , SP in the aPVT may endogenously promote ethanol intake in response to the desire for ethanol induced by OX. Further research is needed to determine whether SP in the aPVT is actually involved in the process of drug seeking and if this SP-induced seeking is prevented by blockade of endogenous OX signaling.
In light of evidence that OX-B preferentially targets OX2R and OX-A targets both OX2R and OX1R (Sakurai et al. 1998) , our findings here implicate OX2R as the receptor responsible for many of the effects described. In the aPVT, OX-B was found to induce larger effects than OX-A, on ethanol drinking as well as SP expression. This is consistent with electrophysiological studies, showing OX-B to be more potent than OX-A in depolarizing and exciting neurons in the PVT (Ishibashi et al. 2005; Huang et al. 2006) . Specifically, while a large majority of neurons in the PVT respond to one or both OX isoforms, their increase in firing rate is larger for OX-B than for OX-A at the same concentration (Ishibashi et al. 2005; Kolaj et al. 2014) . This indicates that it is binding of OX2R that is primarily responsible for OX-induced neuronal activation in the PVT. This is substantiated by our recent finding that ethanol drinking is decreased by an antagonist of OX2R but not OX1R in the aPVT (Barson et al. 2015) . The present results thus support a role specifically for OX2R in the aPVT in promoting ethanol intake and suggest that OX2R may also be the primary OX receptor involved in the aPVTinduced increase in SP expression.
Together, our findings support the participation of the PVT in the addiction neurocircuitry and demonstrate that certain neuropeptides in this nucleus have subregion-specific effects on substance intake, with the aPVT rather than the pPVT being the subregion involved in ethanol drinking. Most importantly, these results point to SP as a potential target for the treatment of addictive behavior.
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